ArticleHepatic medicine : evidence and research2026
Effects of Zaozhu Yinchen Decoction on a Rat Model of Nonalcoholic Steatohepatitis via Regulation of Myeloid-Derived Suppressor Cells.
Article in Hepatic medicine : evidence and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To observe the therapeutic effect of Zaozhu Yinchen Decoction (ZZYC) on rats with non-alcoholic steatohepatitis (NASH) and explore its mechanism of action related to myeloid-derived suppressor cells (MDSCs). Methods: A NASH rat model was established by feeding a high-fat diet for 16 weeks, and drug intervention was initiated from the 9th week of modeling, lasting for 8 weeks. The general status of rats was observed. Biochemical methods were used to detect the activities of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as the triglyceride (TG) content in liver tissue. Hematoxylin-eosin (HE) staining and Oil Red O staining were performed to observe the pathological changes of liver tissue. Flow cytometry was used to detect the expression level of MDSCs in peripheral blood. Enzyme-linked immunosorbent assay (ELISA) was employed to determine the protein expression levels of arginase 1 (ARG-1) and the pro-inflammatory factor S100 calcium-binding protein A9 (S100A9) in liver tissue. Results: Compared with the normal group, rats in the model group exhibited typical histological features of NASH. After treatment with ZZYC decoction, hepatocellular steatosis and inflammatory infiltration were significantly alleviated. Compared with the normal group, the model group showed a significant increase in liver weight, serum ALT and AST activities, liver TG and free fatty acid (FFA) content, peripheral blood MDSC level, and the expression of ARG-1 and S100A9 in liver tissue (all P<0.01). These indicators were significantly reduced after ZZYC decoction treatment (all P<0.05). Conclusion: ZZYC decoction exerts a significant pharmacological effect on improving hepatocellular steatosis, ballooning degeneration, and inflammation in NASH rats. Meanwhile, it can markedly reduce the level of peripheral blood MDSCs and the expression of ARG-1 and S100A9 in liver tissue. These findings suggest that the therapeutic mechanism of ZZYC decoction for NASH is closely associated with the regulation of MDSCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.